Benzinga · Aug 13, 2026
UBS Maintains Neutral on Accendra Health, Lowers Price Target to $1.5
UBS analyst Kevin Caliendo maintains Accendra Health (NYSE:ACH) with a Neutral and lowers the price target from $4.5 to $1.5.
AC
NYSE · ACH
Accendra Health, Inc.
Healthcare · Medical - Distribution
$1.13
Up+$0.06 (+5.61%)
Updated Aug 19, 2026, 7:17 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 187.18M
- P/E ratio
- -0.17
- Dividend yield
- 0.00%
- 52-week range
- $0.93 – $4.69
- Volume
- 3.77M
- Avg. volume
- 1.59M
Price performance
ACH price history
1M range · 21 trading sessions · Daily adjusted prices
ACH closed at $1.13 after 21 trading sessions, down 66.96% for the selected period.
- Last close
- $1.13
- Period change
- -66.96%
- Period low
- $0.95
- Period high
- $3.42
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $1.05 | $1.13 | $0.9613 | $1.13 | 3.77M |
| Aug 17, 2026 | $0.9621 | $1.07 | $0.95 | $1.07 | 2.81M |
| Aug 14, 2026 | $1.08 | $1.09 | $0.9337 | $0.9509 | 2.92M |
| Aug 13, 2026 | $1.19 | $1.2099 | $1.085 | $1.10 | 2.9M |
| Aug 12, 2026 | $1.24 | $1.346 | $1.19 | $1.21 | 2.05M |
| Aug 11, 2026 | $1.38 | $1.38 | $1.20 | $1.26 | 3.24M |
| Aug 10, 2026 | $1.74 | $1.74 | $1.24 | $1.40 | 8.09M |
| Aug 7, 2026 | $2.96 | $3.215 | $2.745 | $2.80 | 1.15M |
| Aug 6, 2026 | $2.97 | $3.0383 | $2.91 | $2.92 | 1.28M |
| Aug 5, 2026 | $2.92 | $3.21 | $2.79 | $2.96 | 1.06M |
| Aug 4, 2026 | $3.48 | $3.56 | $2.865 | $2.94 | 1.69M |
| Aug 3, 2026 | $3.12 | $3.455 | $3.10 | $3.41 | 528.15K |
| Jul 31, 2026 | $3.33 | $3.3783 | $3.00 | $3.09 | 610.91K |
| Jul 30, 2026 | $3.35 | $3.36 | $3.14 | $3.34 | 502.73K |
| Jul 29, 2026 | $3.20 | $3.34 | $3.13 | $3.32 | 491.31K |
| Jul 28, 2026 | $3.25 | $3.27 | $3.12 | $3.25 | 262.07K |
| Jul 27, 2026 | $3.19 | $3.32 | $3.16 | $3.22 | 240.84K |
| Jul 24, 2026 | $3.11 | $3.165 | $3.0501 | $3.14 | 343.51K |
| Jul 23, 2026 | $3.14 | $3.16 | $2.97 | $3.13 | 498.81K |
| Jul 22, 2026 | $3.44 | $3.47 | $3.145 | $3.16 | 300.78K |
| Jul 21, 2026 | $3.37 | $3.535 | $3.3123 | $3.42 | 492.22K |
Latest ACH news
The latest Smart Investors Daily articles mentioning ACH.
Stock researchCompany · Overview
ACH research
Overview
Company profile and research snapshot.
Company profile
Accendra Health Inc is a nationwide provider of products, technology, and services that support health beyond the hospital by connecting patients, providers, and insurers. Through its brands, Apria and Byram Healthcare, the company delivers disposable medical supplies, integrated home healthcare equipment, and related services that help improve health outcomes and quality of life for individuals with chronic, complex, and acute health conditions. Its offerings span diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment, along with patient support services. The company also supplies a broad range of home medical equipment and patient care products, including ostomy, wound care, urology, and incontinence solutions.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $12.39
- Implied upside
- —
- Analysts
- 2
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | UBS | Neutral | — |
| Aug 11, 2026 | Citigroup | Neutral | — |
| Jul 24, 2026 | Citigroup | Buy | — |
| May 12, 2026 | Baird | Outperform | — |
| May 12, 2026 | Citigroup | Buy | — |
News briefing
No generated briefing is available yet.
Fintel · Aug 12, 2026
Citigroup Downgrades Accendra Health (ACH)
Benzinga · Aug 11, 2026
Citigroup Downgrades Accendra Health to Neutral, Lowers Price Target to $1.5
Citigroup analyst Daniel Grosslight downgrades Accendra Health (NYSE:ACH) from Buy to Neutral and lowers the price target from $4.5 to $1.5.
SeekingAlpha · Aug 10, 2026
Accendra Health, Inc. (ACH) Q2 2026 Earnings Call Transcript
Accendra Health, Inc. (ACH) Q2 2026 Earnings Call August 10, 2026 8:00 AM EDTCompany ParticipantsWill Parrish - Vice President of Strategy of Corporate...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
